News - Phoenix Clinical Research

Beyond the Protocol: What the Evidence Says About Patient Support Programs in the MENA Region

There’s a moment that repeats itself in different forms across every Patient Support Program (PSP) I oversee: the moment a program stops being a document on my desk and becomes…

Decentralized Clinical Trials in MENA: Navigating Challenges and Unlocking Opportunities

When I first coordinated a home trial visit for a patient with a rare metabolic disorder watchinga trained research nurse arrive at a family’s door in a Gulf city, cold…

Rare Diseases Clinical Trials in MENA: Challenges and Opportunities with Phoenix Clinical Reserach

The Middle East and North Africa (MENA) region is currently witnessing a transformative shift in its clinical research landscape. The region is now emerging as a critical hub for rare…

Provided by Department of Health – Abu Dhabi, Innovative Gene Transfer Therapy Administered For Duchenne Muscular Dystrophy for First Time in Abu Dhabi

Department of Health – Abu Dhabi (DoH) has provided revolutionary gene transfer therapy for Duchenne muscular dystrophy for the first time in the emirate. The treatment was carried out…

ILIKOS Consulting Group and PHOENIX Clinical Research Announce Strategic Partnership

As the timeframe to develop a new therapy or technology is increasing along with competitive and high-risk nature of the industry, exploring emerging regions that offer better Patient access while…

Challenges of the MENA region and how we overcome them

Challenges of the MENA region and how we overcome them Conducting clinical trials in the Middle East and North Africa (MENA) region offers a multitude of opportunities, yet it also…

Why Small-Medium Biotechs need MENA.

The Middle East and North Africa (MENA) region presents a unique landscape for clinical research, particularly for studies focused on orphan diseases and rare genetic conditions. While these diseases might…

Audiologic and vestibular assessment in children and adolescents with transfusion dependent beta thalassemia major: The era of deferasirox film coated tablet

Abstract Background Hearing impairment has frequently been described in β-thalassemia patients with a significant impact on the patients’ quality of life. Most studies provided evidence of deferoxamine (DFO) dose-related ototoxicity, however, the data is…

How can we support you?